Asthma Canada Research

Conducted by: Asthma Canada

Intro to be added here.

Conducted by: Asthma Canada

Biologic therapies have demonstrated benefits for individuals with severe asthma, including reduced daily symptoms and severe exacerbations. However, data describing patient perspectives on these treatments are limited. This research provides insight into patient-based treatment priorities and preferences for biologics, which may help inform decision-making related to emerging therapies for severe asthma.

Conducted by: Asthma Canada

As part of the PRECISION programme, Asthma Canada helped to develop a Delphi consensus project to define standards of care for severe asthma in Canada, in areas where the evidence is lacking through patient and healthcare professional consensus, to complement forthcoming guidelines. Implementation of these recommendations across the severe asthma care pathway in Canada has the potential to improve outcomes for patients through earlier detection of undiagnosed severe asthma, reduction in time to severe asthma diagnosis, and initiation of advanced phenotype specific therapies.

Conducted by: Asthma Canada

This paper builds upon the core recommendations outlined in the Delphi consensus project of implementing change across the asthma and severe asthma treatment pathways in Canada. Taking a more proactive approach to severe asthma has the potential to improve patient outcomes through earlier diagnosis and treatment, whilst alleviating pressure on the health system.

Conducted by: Asthma Canada

We connected with our community through an online survey to ask what they are most interested in, which of our programs and services they find most helpful, and what they would like to see more of from Asthma Canada. 

Conducted by: Asthma Canada

We connected with our community through an online survey to understand ongoing asthma management and experience as COVID-related restrictions and policies lifted and changed throughout most parts of Canada in 2022.

Conducted by: Asthma Canada

Our third annual survey report revealed the social, financial and health impacts of asthma on the lives of Canadians. 

Conducted by: Asthma Canada

In March 2021, we reached out to our community with an invitation to share their experience of accessing health care during the pandemic. 

Conducted by: Asthma Canada

When Asthma Canada began preparing to launch our 2020 survey, we had no idea what the year would have in store for us. It is safe to say that 2020 is a year unlike any other. The voices of our asthma community — including patients, parents, caregivers and healthcare providers — are especially important during these difficult times, and Asthma Canada continues to meet the changing needs of our community.

Conducted by: Asthma Canada

Our inaugural annual survey report, A Snapshot of Asthma in Canada, revealed the far-reaching impacts of asthma on the health and everyday lives of Canadians. The report shows that lack of access to medications and proper management are critical issues in the community. Associated conditions like mental health issues are impacting the overall management of asthma. Three high-risk groups were identified:  people with low income, those with Severe Asthma, and young adults between 18 and 34 living with asthma, who are disproportionately impacted by the disease.

Conducted by: Asthma Canada

Our study, Severe Asthma: The Canadian Patient Journey revealed the social, financial and health impacts of Severe Asthma on the lives of Canadians. This landmark study is now used to educate, raise awareness and advocate on behalf of the estimated 150,000 – 250,000 Canadians living with Severe Asthma.

Conducted by: Asthma Canada

Mapping the Patient Journey is meant to be used by global and national organizations in collaboration with community partners and patient population group(s) of interest to implement the Severe Asthma Study in order to map out the patient(s) journey with a severe health condition.

Mapping the Patient Journey includes a program background with detailed information about the Severe Asthma Study, the conception of the study, goals and outcomes, as well as detailed information on the process taken to implement the study.

Conducted by: Asthma Canada

We support collaboration with community and corporate partners on research that furthers treatment options. In 2016 we worked with Teva Canada in an epidemiological study of the patterns, causes and effects of eosinophilic asthma to better understand the size and scale of the Severe Asthma community. We are proud to have been a part of this study, which leads to a better understanding of eosinophils, a biomarker found in the blood and its relation to asthma, which may lead to the development of more personalized treatments.

Conducted by: Asthma Canada

Building on prior qualitative research, this study uses a discrete choice experiment to explore how individuals with severe asthma evaluate and prioritize key attributes of biologic treatments. By eliciting patient preferences in a structured, quantitative format, this research contributes to a deeper understanding of how treatment features influence decision-making. These insights may support more patient-centered approaches in the development, evaluation, and delivery of biologic therapies for severe asthma.

Conducted by: Asthma Canada

Asthma and chronic rhinosinusitis with nasal polyps (CRSwNP) are chronic, often co-occurring conditions linked to Type 2 inflammation. In collaboration with international partners, we set out to understand the real-world impact of these diseases and how individuals perceive biologic therapies used in their treatment. By capturing patient experiences across multiple countries, the research supports more informed, patient-centered approaches to managing chronic respiratory conditions.

Conducted by: Asthma Canada

Asthma Canada collaborated on this national study to investigate prescription patterns of oral corticosteroids (OCS) and short-acting β2-agonists (SABA) in asthma care across Canada. Given the risks associated with overuse, the research aimed to quantify usage trends and identify opportunities to optimize asthma treatment. By examining real-world data, this work seeks to inform evidence-based strategies to improve asthma management and reduce reliance on medications linked to poor disease control.